Come Forth 1E10 anti-idiotype vaccine: Delivering the promise to immunotherapy of small cell lung cancer

Cancer Biology and Therapy

Volumn 6, Issue 2, 2007, Pages 151-152

  Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti idiotype antibody; Cancer vacines; Immunotherapy; SCLC

Indexed keywords

CANCER VACCINE; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1E10; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; HUMAN; LUNG SMALL CELL CANCER; MELANOMA; NONHUMAN; NOTE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 34247344501     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.2.4027     Document Type: Note

References (16)

1. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, Hsu AA, Eng P, Koong HN, Thirugnanam A, Tan EH. Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. Lung Cancer. 2007; [Epub ahead of print].
2. Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Semin Oncol 2004; 31(1 Suppl 1):106-11.
3. Blackhall FH, Shepherd FA. Small cell lung cancer and targeted therapies. Curr Opin Oncol 2007; 19:103-8.
4. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM Ab to oncofetal antigen. J Natl Cancer Inst 1981; 66:249-54.
5. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Jones-Calves M, Helling F, Ritter G, Oettgen HF, Old LJ. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1036-44.
6. Grant SC, Kris MG, Miller V, Yao TJ, Houghton AN. Long-term survival in 15 patients with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: an update. Proc Am Soc Clin Oncol 1997; 16:454a.
7. Dai WJ, Hemphill A, Waldvogel A, Ingold K, Deplazes P, Mossmann H, Gottstein B. Major carbohydrate antigen of Echinococcus multilocularis induces an immunoglobulin G response independent of alphabeta+ CD4+ T cells. Infect Immun 2001; 69:6074-83.
8. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998; 58:2844-9.
9. Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C, Kieber-Emmons T. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int J Mol Med 2006; 17:1045-52.
10. Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, Chakraborty M, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 1998; 4:1117-24.
11. Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J, Swoboda R, Strittmatter W, Li W, Luckenbach A, Song H, Li J, Sproesser K, Guerry D, Nair S, Furukawa K, Herlyn D. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother 2003; 52:145-54.
12. Kotani A, Okazaki IM, Muramatsu M, Kinoshita K, Begum NA, Nakajima T, Saito H, Honjo T. A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc Natl Acad Sci USA 2005; 102:4506-11.
13. de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006; 55:443-50.
14. Vazquez AM, Gabri MR, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE, Perez R. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 2000; 7:751-6.
15. Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, Combet T, Perez R, Vazquez AM. Active Immunotherapy with 1E10 Anti-Idiotype Vaccine in Patients with Small Cell Lung Cancer: Report of a Phase I Trial. Cancer Biol Ther 2007; 6[Epub ahead of print].
16. Guthmann M, Castro M, Cinat G, Venier C, Koliren L, Bitton F, Vázquez A, Fainboim L. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an Anti-Idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 2006; 29:215-23.